[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100490052":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":10,"responsibleParty":33,"collaborators":10,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":10,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":10},{"fullName":5,"class":6},"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Prospective Sample Collection",null,"Prospective sample collection from participants treated with HIPEC combined PD1\u002FPDL1inhibitor at Affiliated Cancer Hospital \\& Institute of Guangzhou Medical University under standard of care treatment. Blood and tissue samples will be collected prior to initiation of conversion therapy. And thereafter at the four time points: before and after surgery(±7 days), before the start of the second cycle of adjuvant, tumour progression, blood sample will be collected too.",[13],"Other: Observational",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Observational","All patients will be treated with standard of conversion treatment with HIPEC combined PD1\u002FPDL1 inhibitor. After obtaining written informed consent, participants will have serial blood, tumor tissue collection. The blood collection (10 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. Participants will remain on the study for as long as they are being followed or treated at Affiliated Cancer Hospital \\& Institute of Guangzhou Medical University. Participants can withdraw from the study at any time.",[9],[20],{"name":21,"affiliation":5,"role":22},"Shuzhong Cui, Doctor","PRINCIPAL_INVESTIGATOR",[24,30],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},"Ziying Lei, Doctor","CONTACT","(086)020-66673666","3772","leiziyinggz@126.com",{"name":21,"role":26,"phone":31,"phoneExt":10,"email":32},"0086-138-0251-3800","cuishuzhong@gzhmu.edu.cn",{"type":34,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100490052","biomarker-analysis-of-hipec-combined-with-pd1pdl1-inhibitor-for-gastric-cancer-with-peritoneal-metastasis-100490052",false,"NCT05661110","Biomarker Analysis of HIPEC Combined With PD1\u002FPDL1 Inhibitor for Gastric Cancer With Peritoneal Metastasis","Integrated Biomarker Analysis for Hyperthermic Intraperitoneal Chemotherapy(HIPEC) Combined PD1\u002FPDL1 Inhibitor Treatment in Patients of Advanced Gastric Cancer With Peritoneal Metastasis","Inclusion Criteria:\n\n1. Advanced gastric (gastroesophageal junction) adenocarcinoma confirmed by histology;\n2. Age 18-75 years, Male or Non-pregnant female\n3. Eastern Cooperative Oncology Group(ECOG): 0\\~1；\n4. Negative for human epidermal growth factor receptor 2(HER-2) by immunocytochemistry or fluorescence in situ hybridization；\n5. The presence of gastric cancer peritoneal metastasis is confirmed by laparoscopic exploration, and the PCI≤20；\n6. Patients had received HIPEC combined with PD1\u002FPDL1 inhibitor conversion therapy.\n7. Signed the Informed Consent Form, and blood and tissue samples can be obtained;\n\nExclusion Criteria:\n\n1. Other distal metastases besides peritoneal metastases (e.g., liver, lung, pleural, brain, bone metastases, etc.);\n2. Other patients who were considered unsuitable for inclusion by the researchers;","ALL","18 Years","75 Years",{"count":46,"type":47},46,"ESTIMATED","OBSERVATIONAL","A single-center, observational study, integrated biomarker analysis of HIPEC combined Programmed cell death 1 \u002FProgrammed cell death 1 ligand 1(PD1\u002FPDL1)inhibitor in previously treated patients of advanced gastric cancer with peritoneal metastasis. Tests will be performed on tumor tissue and blood samples, and imaging assessments will be reviewed in order to monitor how well each patient responds to treatment. This is an observational study, so participants will not receive cancer treatment, other than the treatment received as standard of care.",[51],"Gastric Cancer",[53],"Biomarker","NOT_YET_RECRUITING","2022-12-13",{"date":57,"type":58},"2022-12-22","ACTUAL",{"date":60,"type":47},"2023-01-01",{"date":62,"type":47},"2027-12-31",{"name":5,"class":6}]